Bactiguard Sets 2030 Growth Targets as It Shifts to License-Based MedTech Model

Bactiguard Holding AB ( ($SE:BACTI.B) ) has issued an update.

Bactiguard is a global MedTech company specializing in infection prevention, primarily through an ultra-thin noble metal coating that prevents bacterial attachment and biofilm formation on medical devices. Its technology, validated over more than three decades for safety and effectiveness, is used today in urology and orthopedics and supported by a wound management portfolio featuring Hydrocyn aqua and specialty sutures.

The company is undergoing a strategic transformation from selling its own coated medical devices to a license-based partnership model with leading MedTech companies to scale adoption of its technology. For 2030, Bactiguard targets at least SEK 600 million in revenue, SEK 200 million in EBITDA, and at least ten application areas under exclusive or license partnerships, aiming to make its infection-preventing coating a global standard of care and significantly expand its role in reducing device-related infections worldwide.

More about Bactiguard Holding AB

Bactiguard is a global MedTech company specializing in infection prevention through an ultra-thin noble metal coating applied to medical devices. Its technology, proven safe and biocompatible over more than 30 years, is currently used in urology and orthopedics, complemented by a wound management portfolio including Hydrocyn aqua and specialty sutures.

The company is shifting from manufacturing its own coated devices to a license-focused model, partnering with major MedTech firms to broaden market reach and reduce healthcare burdens from infections.

Average Trading Volume: 9,745

Technical Sentiment Signal: Sell

Current Market Cap: SEK576.5M

For an in-depth examination of BACTI.B stock, go to TipRanks’ Overview page.